Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -4.78 is 3422% below its 5-year average of -0.14, near the low end of its 5-year range (-4.78–3.14).
As of the fiscal period ended Tuesday, June 30, 2026. 289.60% below its 12-month average of -1.23.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -4.78.
DEBT TO EQUITY RATIO
-4.78
DEBT TO EQUITY RATIO AVG TTM
-1.23
DEBT TO EQUITY RATIO AVG 3Y
-0.15
DEBT TO EQUITY RATIO AVG 5Y
-0.14
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-289.60%
CURRENT VS 3Y AVG
-3078.99%
CURRENT VS 5Y AVG
-3422.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 766 covered companies
CURRENT VS SECTOR MEDIAN
-4444.85%
vs the sector median at left
Jupiter Neurosciences, Inc.
Market Cap
$1.40M
Debt to Equity Ratio
-4.78
TTM Avg
-1.23
3Y Avg
-0.15
5Y Avg
-0.14
Market Cap
$1.43M
Debt to Equity Ratio
0.24
TTM Avg
0.63
3Y Avg
2.77
5Y Avg
1.75
Market Cap
$1.37M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.47M
Debt to Equity Ratio
0.83
TTM Avg
0.17
3Y Avg
0.16
5Y Avg
0.13
Market Cap
$1.48M
Debt to Equity Ratio
0.02
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.40M | -4.78 | -1.23 | -0.15 | -0.14 |
| Curis, Inc. (CRIS)vs › | $1.46M | 0.22 | 0.30 | 0.17 | 0.13 |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | 0.24 | 0.63 | 2.77 | 1.75 |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | 1.51 | 0.59 | 0.51 | 3.40 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.37M | 0.01 | 0.02 | 0.01 | 0.01 |
| Genprex, Inc. (GNPX)vs › | $1.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | 0.83 | 0.17 | 0.16 | 0.13 |
| NewcelX Ltd. (NCEL)vs › | $1.32M | 0.06 | 0.03 | 0.02 | 0.01 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | 0.02 | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.60M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
-4.78
Current Ratio
0.66
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -4.78 |
| 2026-03-31 | -1.74 |
| 2025-12-31 | -2.90 |
| 2025-09-30 | 3.14 |
| 2025-06-30 | 0.14 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | 0.05 |
| 2024-09-30 | -0.41 |
| 2024-06-30 | -0.44 |
| 2024-03-31 | -0.38 |
| 2023-12-31 | -0.39 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-06-30 | -0.20 |
| 2022-03-31 | -0.12 |
| 2021-12-31 | -0.13 |
| 2021-09-30 | -0.14 |
| 2021-06-30 | -0.09 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -0.03 |
| 2020-09-30 | 0.00 |
